Annual FCF
-$60.40 M
-$39.40 M-187.60%
December 31, 2024
Summary
- As of March 9, 2025, ARCT annual free cash flow is -$60.40 million, with the most recent change of -$39.40 million (-187.60%) on December 31, 2024.
- During the last 3 years, ARCT annual FCF has risen by +$78.05 million (+56.38%).
- ARCT annual FCF is now -348.88% below its all-time high of $24.27 million, reached on December 31, 2022.
Performance
ARCT Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$284.00 K
+$23.56 M+98.81%
December 31, 2024
Summary
- As of March 9, 2025, ARCT quarterly free cash flow is -$284.00 thousand, with the most recent change of +$23.56 million (+98.81%) on December 31, 2024.
- Over the past year, ARCT quarterly FCF has increased by +$30.19 million (+99.07%).
- ARCT quarterly FCF is now -100.18% below its all-time high of $156.45 million, reached on December 31, 2022.
Performance
ARCT Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$60.40 M
+$1.22 M+1.98%
December 31, 2024
Summary
- As of March 9, 2025, ARCT TTM free cash flow is -$60.40 million, with the most recent change of +$1.22 million (+1.98%) on December 31, 2024.
- Over the past year, ARCT TTM FCF has increased by +$10.76 million (+15.13%).
- ARCT TTM FCF is now -144.10% below its all-time high of $136.96 million, reached on September 30, 2023.
Performance
ARCT TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
ARCT Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -187.6% | +99.1% | +15.1% |
| 3 y3 years | +56.4% | +99.4% | +65.7% |
| 5 y5 years | -731.5% | +99.4% | +65.7% |
ARCT Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -348.9% | +56.4% | -100.2% | +99.4% | -144.1% | +65.7% |
| 5 y | 5-year | -348.9% | +56.4% | -100.2% | +99.4% | -144.1% | +65.7% |
| alltime | all time | -348.9% | +56.4% | -100.2% | +99.4% | -144.1% | +65.7% |
Arcturus Therapeutics Holdings Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$60.40 M(+187.6%) | -$284.00 K(-98.8%) | -$60.40 M(-2.0%) |
| Sep 2024 | - | -$23.84 M(-21.7%) | -$61.62 M(-13.4%) |
| Jun 2024 | - | -$30.47 M(+425.6%) | -$71.16 M(-828.7%) |
| Mar 2024 | - | -$5.80 M(+285.4%) | $9.77 M(-146.5%) |
| Dec 2023 | -$21.00 M(-186.5%) | -$1.50 M(-95.5%) | -$21.00 M(-115.3%) |
| Sep 2023 | - | -$33.39 M(-166.2%) | $136.96 M(+8.9%) |
| Jun 2023 | - | $50.45 M(-238.0%) | $125.75 M(+223.6%) |
| Mar 2023 | - | -$36.56 M(-123.4%) | $38.85 M(+60.1%) |
| Dec 2022 | $24.27 M(-117.5%) | $156.45 M(-450.9%) | $24.27 M(-113.8%) |
| Sep 2022 | - | -$44.59 M(+22.4%) | -$175.80 M(+17.5%) |
| Jun 2022 | - | -$36.44 M(-28.8%) | -$149.63 M(+2.1%) |
| Mar 2022 | - | -$51.15 M(+17.3%) | -$146.53 M(+5.8%) |
| Dec 2021 | -$138.45 M(+210.4%) | -$43.62 M(+136.8%) | -$138.45 M(+35.5%) |
| Sep 2021 | - | -$18.42 M(-44.8%) | -$102.16 M(+2.1%) |
| Jun 2021 | - | -$33.35 M(-22.6%) | -$100.06 M(+32.2%) |
| Mar 2021 | - | -$43.07 M(+487.6%) | -$75.67 M(+69.7%) |
| Dec 2020 | -$44.60 M(+514.1%) | -$7.33 M(-55.1%) | -$44.60 M(-1.2%) |
| Sep 2020 | - | -$16.31 M(+82.0%) | -$45.13 M(+41.9%) |
| Jun 2020 | - | -$8.96 M(-25.3%) | -$31.81 M(+130.9%) |
| Mar 2020 | - | -$12.00 M(+52.8%) | -$13.77 M(+89.6%) |
| Dec 2019 | -$7.26 M(-67.3%) | -$7.85 M(+162.2%) | -$7.26 M(+34.5%) |
| Sep 2019 | - | -$3.00 M(-133.0%) | -$5.40 M(-42.9%) |
| Jun 2019 | - | $9.07 M(-265.3%) | -$9.45 M(-65.0%) |
| Mar 2019 | - | -$5.49 M(-8.3%) | -$27.00 M(+21.4%) |
| Dec 2018 | -$22.24 M | -$5.99 M(-15.0%) | -$22.24 M(+95.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$7.05 M(-16.9%) | -$11.40 M(+84.9%) |
| Jun 2018 | - | -$8.48 M(+1072.8%) | -$6.17 M(-274.6%) |
| Mar 2018 | - | -$723.00 K(-114.9%) | $3.53 M(-596.6%) |
| Dec 2017 | -$711.00 K(-80.0%) | $4.85 M(-367.4%) | -$711.00 K(-111.6%) |
| Sep 2017 | - | -$1.81 M(-248.9%) | $6.14 M(+382.7%) |
| Jun 2017 | - | $1.22 M(-124.5%) | $1.27 M(-131.4%) |
| Mar 2017 | - | -$4.96 M(-142.4%) | -$4.05 M(+14.2%) |
| Dec 2016 | -$3.55 M(-144.1%) | $11.70 M(-275.1%) | -$3.55 M(-152.5%) |
| Sep 2016 | - | -$6.68 M(+62.7%) | $6.75 M(-15.5%) |
| Jun 2016 | - | -$4.11 M(-7.9%) | $8.00 M(-2.4%) |
| Mar 2016 | - | -$4.46 M(-120.3%) | $8.19 M(+1.8%) |
| Dec 2015 | $8.04 M(-128.3%) | $22.00 M(-504.6%) | $8.04 M(-137.1%) |
| Sep 2015 | - | -$5.44 M(+38.9%) | -$21.70 M(-15.8%) |
| Jun 2015 | - | -$3.92 M(-15.0%) | -$25.76 M(-5.8%) |
| Mar 2015 | - | -$4.61 M(-40.5%) | -$27.33 M(-3.8%) |
| Dec 2014 | -$28.41 M(+284.3%) | -$7.74 M(-18.5%) | -$28.41 M(+11.3%) |
| Sep 2014 | - | -$9.50 M(+73.1%) | -$25.51 M(+41.6%) |
| Jun 2014 | - | -$5.49 M(-3.3%) | -$18.02 M(+39.8%) |
| Mar 2014 | - | -$5.68 M(+17.1%) | -$12.89 M(+74.4%) |
| Dec 2013 | -$7.39 M(+367.0%) | -$4.85 M(+141.8%) | -$7.39 M(+190.6%) |
| Sep 2013 | - | -$2.00 M(+460.1%) | -$2.54 M(+372.0%) |
| Jun 2013 | - | -$358.00 K(+97.8%) | -$539.00 K(+197.8%) |
| Mar 2013 | - | -$181.00 K | -$181.00 K |
| Dec 2012 | -$1.58 M(-33.6%) | - | - |
| Dec 2011 | -$2.38 M | - | - |
FAQ
- What is Arcturus Therapeutics Holdings annual free cash flow?
- What is the all time high annual FCF for Arcturus Therapeutics Holdings?
- What is Arcturus Therapeutics Holdings annual FCF year-on-year change?
- What is Arcturus Therapeutics Holdings quarterly free cash flow?
- What is the all time high quarterly FCF for Arcturus Therapeutics Holdings?
- What is Arcturus Therapeutics Holdings quarterly FCF year-on-year change?
- What is Arcturus Therapeutics Holdings TTM free cash flow?
- What is the all time high TTM FCF for Arcturus Therapeutics Holdings?
- What is Arcturus Therapeutics Holdings TTM FCF year-on-year change?
What is Arcturus Therapeutics Holdings annual free cash flow?
The current annual FCF of ARCT is -$60.40 M
What is the all time high annual FCF for Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings all-time high annual free cash flow is $24.27 M
What is Arcturus Therapeutics Holdings annual FCF year-on-year change?
Over the past year, ARCT annual free cash flow has changed by -$39.40 M (-187.60%)
What is Arcturus Therapeutics Holdings quarterly free cash flow?
The current quarterly FCF of ARCT is -$284.00 K
What is the all time high quarterly FCF for Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings all-time high quarterly free cash flow is $156.45 M
What is Arcturus Therapeutics Holdings quarterly FCF year-on-year change?
Over the past year, ARCT quarterly free cash flow has changed by +$30.19 M (+99.07%)
What is Arcturus Therapeutics Holdings TTM free cash flow?
The current TTM FCF of ARCT is -$60.40 M
What is the all time high TTM FCF for Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings all-time high TTM free cash flow is $136.96 M
What is Arcturus Therapeutics Holdings TTM FCF year-on-year change?
Over the past year, ARCT TTM free cash flow has changed by +$10.76 M (+15.13%)